Sichuan Kelun-Biotech SKB500 Study Results

Sichuan Kelun-Biotech Biopharmaceutical announced the positive first-in-human study results for its novel B7-H3 ADC SKB500 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, United States. Professor Liu Haifeng from Jilin Provincial Cancer Hospital presented the data, which showed broad-spectrum antitumor activity across multiple solid tumor types, including small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), and pancreatic ductal adenocarcinoma (PDAC). Notably, in SCLC patients, the objective response rate (ORR) was 65.0%. The study also demonstrated a favorable safety profile for SKB500, particularly at the 12 mg/kg dose, with a low incidence of severe adverse events and no treatment-related deaths. These findings lay a solid foundation for further clinical development, with a Phase II exploratory study already underway in China for extensive-stage SCLC.